



September 27, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Growth)

Shinya Kurebayashi, President & CEO

Announcement of approval of additional indication of Ranibizumab BS
(Excerpt from Japanese version)

Tokyo, September 27, 2023 – Kidswell Bio Corporation (KWB) is delighted to announce that Senju Pharmaceutical Co., Ltd. received an approval of partial modification of pharmaceutical manufacturing approval for macular edema associated with retinal vein occlusion as additional indication of Ranibizumab BS (Project name: GBS-007) in addition to age-related macular degeneration, choroidal neovascularization due to pathologic myopia and diabetic macular edema.

The impact on the KWB's business and financial situation is expected to be minimal. This expansion of indication of GBS-007 will enhance KWB's corporate value by strengthening the biosimilar business.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com